Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting

Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help r...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2019-02, Vol.140, p.129-135
Main Authors: Fabre, Kristin M., Delsing, Louise, Hicks, Ryan, Colclough, Nicola, Crowther, Damian C., Ewart, Lorna
Format: Article
Language:English
Subjects:
Animals
Bioinformatics
Bioinformatik
Blood
Blood brain barrier
cns
crispr/cas9
differentiation
Drug development
Drug Discovery
Drug products
efficient generation
endothelial-cells
Farmaceutiska vetenskaper
Humans
in-vitro model
Induced Pluripotent Stem Cells
INF502 Biomarkers
INF502 Biomarkörer
inflammation
iPSC
Microphysiological systems
Models, Biological
Neurodegenerative diseases
On chips
Organs-on-chips
penetration
permeability
Pharmaceutical
Pharmaceutical company
Pharmaceutical industry
Pharmaceutical Sciences
Pharmacology & Pharmacy
Physiological models
Physiological response
Stem cells
Tissue chips
Translational Medical Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics. [Display omitted]
ISSN:0169-409X
1872-8294
1872-8294
DOI:10.1016/j.addr.2018.09.009